Breast Cancer Clinical Trial
— DATAOfficial title:
A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.
| Verified date | February 2023 |
| Source | Maastricht University Medical Center |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2-3 years tamoxifen
| Status | Completed |
| Enrollment | 1914 |
| Est. completion date | April 2022 |
| Est. primary completion date | April 2022 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 45 Years to 99 Years |
| Eligibility | Inclusion Criteria: - postmenopausal patients with hormone receptor positive breast cancer who have already received 2 to 3 years of adjuvant tamoxifen, and who never had signs of loco-regional recurrences or distant metastasis Exclusion Criteria: - Previous hormonal therapy as adjuvant breast cancer treatment besides tamoxifen. - Previous history of invasive breast cancer within the last 10 years, other then the breast cancer that is currently treated with tamoxifen |
| Country | Name | City | State |
|---|---|---|---|
| Netherlands | Research Site | Alkmaar | |
| Netherlands | Research Site | Almelo | |
| Netherlands | Research Site | Almere | |
| Netherlands | Research Site | Amersfoort | |
| Netherlands | Research Site | Amstelveen | |
| Netherlands | Research Site | Amsterdam | |
| Netherlands | Research Site | Apeldoorn | |
| Netherlands | Research Site | Arnhem | |
| Netherlands | Research Site | Bergen Op Zoom | |
| Netherlands | Research Site | Beugen | |
| Netherlands | Research Site | Breda | |
| Netherlands | Research Site | Capelle Aan Den IJssel | |
| Netherlands | Research Site | Den Bosch | |
| Netherlands | Research Site | Den Haag | |
| Netherlands | Research Site | Deventer | |
| Netherlands | Research Site | Dirksland | |
| Netherlands | Research Site | Doetinchem | |
| Netherlands | Research Site | Dordrecht | |
| Netherlands | Research Site | Drachten | |
| Netherlands | Research Site | Ede | |
| Netherlands | Research Site | Eindhoven | |
| Netherlands | Research Site | Emmen | |
| Netherlands | Research Site | Enschede | |
| Netherlands | Research Site | Geldrop | |
| Netherlands | Research Site | Geleen | |
| Netherlands | Research Site | Goes | |
| Netherlands | Research Site | Gorinchem | |
| Netherlands | Research Site | Gouda | |
| Netherlands | Research Site | Haarlem | |
| Netherlands | Research Site | Hardenberg | |
| Netherlands | Research Site | Heerenveen | |
| Netherlands | Research Site | Heerlen | |
| Netherlands | Research Site | Hengelo | |
| Netherlands | Research Site | Hilversum | |
| Netherlands | Research Site | Hoofddorp | |
| Netherlands | Research Site | Hoogeveen | |
| Netherlands | Research Site | Hoorn | |
| Netherlands | Research Site | Leeuwarden | |
| Netherlands | Research Site | Leiden | |
| Netherlands | Research Site | Leidschendam | |
| Netherlands | Research Site | Maastricht | |
| Netherlands | Research Site | Nieuwegein | |
| Netherlands | Research Site | Nijmegen | |
| Netherlands | Research Site | Purmerend | |
| Netherlands | Research Site | Roermond | |
| Netherlands | Research Site | Roosendaal | |
| Netherlands | Research Site | Rotterdam | |
| Netherlands | Research Site | Schiedam | |
| Netherlands | Research Site | Sneek | |
| Netherlands | Research Site | Spijkenisse | |
| Netherlands | Research Site | Stadskanaal | |
| Netherlands | Research Site | Terneuzen | |
| Netherlands | Research Site | Tiel | |
| Netherlands | Research Site | Tilburg | |
| Netherlands | Research Site | Uden | |
| Netherlands | Research Site | Utrecht | |
| Netherlands | Research Site | Veldhoven | |
| Netherlands | Research Site | Venlo | |
| Netherlands | Research Site | Vlissingen | |
| Netherlands | Research Site | Winschoten | |
| Netherlands | Research Site | Winterswijk | |
| Netherlands | Research Site | Woerden | |
| Netherlands | Research Site | Zaandam | |
| Netherlands | Research Site | Zevenaar | |
| Netherlands | Research Site | Zoetermeer | |
| Netherlands | Research Site | Zutphen | |
| Netherlands | Research Site | Zwolle |
| Lead Sponsor | Collaborator |
|---|---|
| Maastricht University Medical Center |
Netherlands,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To assess the disease free survival (DFS) with 6 years of adjuvant anastrozole compared with 3 years of adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2 to 3 years of adjuvant tamoxifen | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen | ||
| Secondary | To compare the incidence of contralateral breast cancer after 6 years versus 3 years adjuvant anastrozole, subsequent to 2 to 3 years of tamoxifen | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen | ||
| Secondary | To compare the overall survival after 6 years versus 3 years adjuvant anastrozole, subsequent to 2 to 3 years of tamoxifen | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen | ||
| Secondary | To compare toxicity of 6 years versus 3 years of adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2 to 3 years of tamoxifen | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen | ||
| Secondary | To determine regional differences in the initial treatment of breast cancer retrospectively by collecting baseline information on initial therapies. | Aspects of the initial treatment that will be investigated are e.g. the kind of surgery performed (breast saving or mastectomy) and whether or not chemotherapy is given and which chemotherapy was used in postmenopausal patients in relation to the primary tumour and patient characteristics. | After 9 years | |
| Secondary | To compare the cost effectiveness of 3 years versus 6 years adjuvant anastrozole therapy, after subsequent 2 to 3 years of adjuvant tamoxifen treatment. | After 9 years for the group with 6 years of adjuvant anastrozol, subsequent to 2 to 3 years of adjuvant tamoxifen or after 6 years for the group with 3 years of adjuvant anastrozole subsequent to 2 to 3 years of adjuvant tamoxifen | ||
| Secondary | To assess patterns of care in The Netherlands in prevention, detection and treatment of osteoporosis in postmenopausal women with breast cancer treated with adjuvant anastrozole. | After 9 years | ||
| Secondary | To relate the number of osteoporotic fractures during and following treatment with adjuvant anastrozole with the compliance to osteoporotic guidelines. | After 9 years | ||
| Secondary | To analyse occurrence of distant (bone) metastases in relation to occurrence of osteopenia and osteoporosis, and in relation to use of supplements and therapy for reduced BMD. | After 9 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |